Literature DB >> 17020421

Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.

Michael R Jacobs1, Peter C Appelbaum.   

Abstract

Nadifloxacin is a potent, broad-spectrum, quinolone agent approved for topical use in acne vulgaris and skin infections in Japan. As exposure of pathogenic and colonising bacteria to antibiotics results in drug resistance, it is not desirable to use an important, broad-spectrum antibiotic, which belongs to a class of agents widely used systemically to treat a wide variety of infections, as a topically applied preparation. On this basis, nadifloxacin is not a good option for topical treatment of acne when other effective non-antibiotic treatments are available. Nadifloxacin has potential as a topical agent for short-term treatment of skin infections. The arginine salt of its (-)-(S)-isomer is being developed as a parenteral agent based on its potency against methicillin and quinolone-resistant Staphylococcus aureus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020421     DOI: 10.1517/14656566.7.14.1957

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  10 in total

Review 1.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 2.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

3.  Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Ravindra Yeole; Anasuya Patel; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

4.  Impact of Parallel Topical Treatment with Nadifloxacin and Adapalene on Acne Vulgaris Severity and Quality of Life: A Prospective, Uncontrolled, Multicentric, Noninterventional Study.

Authors:  Claudia Neumeister; Rolf-Hasso Bödeker; Ulrich Schwantes; Claudia Borelli
Journal:  Biomed Hub       Date:  2021-12-20

5.  Antimicrobial Susceptibility, Biotypes and Phylotypes of Clinical Cutibacterium (Formerly Propionibacterium) acnes Strains Isolated from Acne Patients: An Observational Study.

Authors:  Nanxue Zhang; Ruoyue Yuan; Kevin Z Xin; Zhong Lu; Ying Ma
Journal:  Dermatol Ther (Heidelb)       Date:  2019-09-19

Review 6.  Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence.

Authors:  Sachin S Bhagwat; Manohar Nandanwar; Atul Kansagara; Anusuya Patel; Swapna Takalkar; Rajesh Chavan; Hariharan Periasamy; Ravindra Yeole; Prasad K Deshpande; Satish Bhavsar; Ashima Bhatia; Jaishid Ahdal; Rishi Jain; Mahesh Patel
Journal:  Drug Des Devel Ther       Date:  2019-12-24       Impact factor: 4.162

Review 7.  Recent advances in the chemistry of 2-chloroquinoline-3-carbaldehyde and related analogs.

Authors:  Wafaa S Hamama; Mona E Ibrahim; Ayaa A Gooda; Hanafi H Zoorob
Journal:  RSC Adv       Date:  2018-02-23       Impact factor: 4.036

Review 8.  Fluoroquinolones Hybrid Molecules as Promising Antibacterial Agents in the Fight against Antibacterial Resistance.

Authors:  Ioana-Andreea Lungu; Octavia-Laura Moldovan; Victoria Biriș; Aura Rusu
Journal:  Pharmaceutics       Date:  2022-08-22       Impact factor: 6.525

Review 9.  Topical Antibacterials in Dermatology.

Authors:  Debabrata Bandyopadhyay
Journal:  Indian J Dermatol       Date:  2021 Mar-Apr       Impact factor: 1.494

10.  Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies.

Authors:  Varsha Narayanan; Salman Motlekar; Ganesh Kadhe; Seema Bhagat
Journal:  Dermatol Ther (Heidelb)       Date:  2014-09-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.